AU Patent

AU2019450366B2 — Use of an RXR agonist in treating Her2+ cancers

Assigned to University of Texas System · Expires 2026-01-08 · 0y expired

What this patent protects

The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise and RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormo…

USPTO Abstract

The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise and RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.

Drugs covered by this patent

Patent Metadata

Patent number
AU2019450366B2
Jurisdiction
AU
Classification
—
Expires
2026-01-08
Drug substance claim
No
Drug product claim
No
Assignee
University of Texas System
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.